Weight Loss
MAZDUTIDE is a research-use product carried by vendors we track, grouped under Weight Loss. For research use only; an editorial review is pending.
MAZDUTIDE is offered by one or more vendors we track. We have not yet written a detailed editorial summary for this compound. The offerings below reflect what vendors currently carry. For research use only — verify dosing, handling, and safety against primary sources.
Where to buy
Some links on this page are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.
Best $/mg
Solution PeptidesTestedMazdutide – 6mg ***DISCONTINUED***– Available only while supplies last!
$80.00
$13.33/mg · 6mg
Evidence level
Preclinical only
A synthetic dual GLP-1 and glucagon receptor co-agonist (IBI362, LY3305677) in late-stage clinical development for obesity and type 2 diabetes. Substantial human trial data, especially from Chinese phase III programs; not yet globally approved.
Mechanism
Mechanism not yet documented.
Researched benefits
Weight loss
Phase II and phase III trials in adults with obesity report mean weight loss of 10–18% at 24–48 weeks at the higher dose ranges (6–9 mg weekly), comparable to semaglutide and approaching tirzepatide in some readouts. Most data is from Chinese cohorts.
Glycemic control
GLP-1 agonism drives glucose-dependent insulin secretion and reduces HbA1c by 1.5–2.0% in T2D trials at therapeutic doses, with low intrinsic hypoglycemia risk.
Hepatic fat reduction
The glucagon-receptor component adds direct effects on hepatic lipid metabolism. Trials in MASLD/MASH show substantial reductions in liver fat fraction beyond what pure GLP-1 agonists achieve.
Energy expenditure
Glucagon agonism increases resting energy expenditure modestly, contributing to the weight-loss profile through both reduced intake and increased output.
Risks & cautions
GI side effects
Nausea, vomiting, diarrhea, and constipation are common, particularly during dose escalation. The pattern is typical of GLP-1 class drugs. Discontinuation rates in trials are similar to semaglutide.
Glucagon-receptor metabolic effects
Pure GCGR agonism raises blood glucose. The balance with GLP-1 keeps net glycemic effect favorable, but at higher doses or in individuals with hepatic disease, the glucagon component can produce undesirable lipolytic or glucose effects.
Pancreatitis and gallbladder events
Class effects of GLP-1 agonists include acute pancreatitis and cholelithiasis. Pre-marketing trials have detected the same signals for Mazdutide.
Thyroid C-cell concern
Rodent thyroid C-cell hyperplasia is a class concern for long-acting GLP-1 agonists. Personal or family history of MTC or MEN2 is a contraindication consistent with the class.
Counterfeit and gray-market sourcing
Mazdutide is not approved in the US or EU. Material sold under this name outside formal supply chains has unverified identity, purity, and dosing.
Dosing
Trial dosing is weekly subcutaneous injection with stepwise escalation. Maintenance doses studied range 3 mg, 4.5 mg, 6 mg, and 9 mg weekly depending on the indication.
Vial sizes
--
Half-life
--
Route
--
Escalation matters — starting at the maintenance dose produces severe GI side effects. Standard protocols titrate every 4 weeks. The drug is long-acting (weekly dosing) and stable in solution under refrigeration.
Contraindications
In depth
Mazdutide originated as a dual incretin agonist program at Eli Lilly (LY3305677) and was licensed to Innovent Biologics for development in China, where it goes by IBI362. It is structurally an oxyntomodulin analog — designed to engage both GLP-1 and glucagon receptors with a tunable ratio (Mazdutide is GLP-1-leaning, roughly 8:1 GLP-1:GCGR potency).
The drug is in late-stage trials and has been approved in China for obesity (2025). It is not approved in the US or EU as of writing. The relevance to this catalog is that Mazdutide is increasingly available through gray-market peptide channels alongside semaglutide and tirzepatide.
Two receptors, one molecule:
The therapeutic rationale for the dual agonism is that glucagon's metabolic effects compound GLP-1's appetite suppression — particularly for hepatic fat reduction, where pure GLP-1 agonists are less effective. Tirzepatide adds GIP rather than glucagon; Survodutide and Mazdutide are the leading GLP-1/GCGR examples.
Substantial and growing:
Western trial data is more limited; the bulk of clinical evidence is Chinese.
Robust in DIO mice, obese non-human primates, and rat models of MASH. Pharmacology is well-characterized at both receptors.
Generally not stacked with other incretin agonists — overlapping mechanism is redundant and amplifies GI side effects. Anecdotal pairings:
Avoid combining with sulfonylureas or insulin without dose adjustment — hypoglycemia risk rises.
References
